Global Information
회사소개 | 문의 | 비교리스트

헤모필루스 인플루엔자 B형 감염증 : 파이프라인 리뷰

Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 255972
페이지 정보 영문 69 Pages
가격
US $ 2,000 ₩ 2,390,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,781,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,172,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


헤모필루스 인플루엔자 B형 감염증 : 파이프라인 리뷰 Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 69 Pages

인플루엔자균 B형(Hib)은 특히 아동에게는 중병으로 연결되는 치명적인 감염증을 일으키는 세균입니다. 증후는 심한 두통, 사경, 경련(발작), 심한 졸음, 각성 곤란, 의식 상실·호흡 곤란 등입니다. 소인은 연령과 면역계 저하 등입니다. 치료에는 항생물질을 사용합니다.

세계의 헤모필루스 인플루엔자 B형 감염증(Haemophilus influenzae Type B Infections) 치료제 개발 동향에 대해 조사했으며, 파이프라인 제품 각 개발 단계의 비교 분석, 약제 표적, 작용기서, 투여 경로, 분자 종류별 치료제 평가 등의 정보를 전해드립니다.

서론

  • 조사 범위

헤모필루스 인플루엔자 B형 감염증 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 치료제
  • 대학/기관별 치료제
  • 기업에서 개발중인 제품
  • 대학/기관에서 연구중인 제품

치료제 평가

  • 표적별
  • 투여 경로별
  • 분자 종류별

헤모필루스 인플루엔자 B형 감염증 치료제 개발에 참여하고 있는 기업

  • Beijing Minhai Biotechnology Co., Ltd
  • Biological E. Limited
  • Daiichi Sankyo Company Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Limited
  • Kaketsuken KK
  • LG Life Science LTD.
  • Panacea Biotec Limited
  • Sanofi
  • Sanofi Pasteur SA
  • Shantha Biotechnics Ltd
  • Zydus Cadila Healthcare Ltd

약제 개요

휴지중인 프로젝트

중지된 프로젝트

부록

KSM 17.06.09

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Haemophilus influenzae Type B Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Biken Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Biological E Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by CanSino Biologics Inc, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by KM Biologics Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by LG Chem Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Liaoning Chengda Co., Ltd., H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Panacea Biotec Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Sanofi Pasteur SA, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Serum Institute of India Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Tuck-More Biotechnology Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Vaxxilon AG, H1 2020
  • Haemophilus influenzae Type B Infections - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
  • Haemophilus influenzae Type B Infections - Dormant Projects, H1 2020
  • Haemophilus influenzae Type B Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Haemophilus influenzae Type B Infections - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Haemophilus influenzae Type B Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape.

Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 7, 7, 2, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Haemophilus influenzae Type B Infections - Overview
    • Haemophilus influenzae Type B Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Haemophilus influenzae Type B Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Biken Co Ltd
    • Biological E Ltd
    • Cadila Healthcare Ltd
    • CanSino Biologics Inc
    • Chongqing Zhifei Biological Products Co Ltd
    • GlaxoSmithKline Plc
    • Hilleman Laboratories Pvt Ltd
    • KM Biologics Co Ltd
    • LG Chem Ltd
    • Liaoning Chengda Co., Ltd.
    • Novo Medi Sciences Pvt Ltd
    • Olymvax Biopharmaceuticals Inc
    • Panacea Biotec Ltd
    • Sanofi Pasteur SA
    • Serum Institute of India Ltd
    • Shantha Biotechnics Pvt Ltd
    • Tuck-More Biotechnology Co Ltd
    • Vaxxilon AG
    • Yisheng Biopharma Co Ltd
  • Haemophilus influenzae Type B Infections - Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BK-1310 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • haemophilus influenza B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • haemophilus influenzae [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Haemophilus influenzae B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Haemophilus influenzae B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Haemophilus influenzae B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-Hib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Haemophilus influenzae Type B Infections - Dormant Projects
  • Haemophilus influenzae Type B Infections - Discontinued Products
  • Haemophilus influenzae Type B Infections - Product Development Milestones
    • Featured News & Press Releases
      • Jan 07, 2019: Biomedical Sciences researcher gets $3.26 million grant to develop universal flu vaccine
      • Jun 24, 2015: Hilleman Laboratories' preclinical trial report on Hib vaccine offers hope to millions of children
      • Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5
      • Nov 10, 2014: Shantha's Pentavalent Pediatric Vaccine launched in India
      • May 05, 2014: Shantha's Pentavalent Pediatric Vaccine prequalified by World Health Organization
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q